Legacy Wealth Asset Management LLC Grows Stake in Genmab A/S Sponsored ADR $GMAB

Legacy Wealth Asset Management LLC increased its position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 164.1% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 102,164 shares of the company’s stock after purchasing an additional 63,484 shares during the quarter. Genmab A/S accounts for 0.6% of Legacy Wealth Asset Management LLC’s investment portfolio, making the stock its 25th biggest holding. Legacy Wealth Asset Management LLC’s holdings in Genmab A/S were worth $2,806,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. CIBC Private Wealth Group LLC increased its position in shares of Genmab A/S by 291.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after buying an additional 616 shares in the last quarter. NewEdge Advisors LLC boosted its position in shares of Genmab A/S by 1,229.0% in the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after buying an additional 1,143 shares in the last quarter. V Square Quantitative Management LLC purchased a new stake in shares of Genmab A/S in the 1st quarter worth about $34,000. Brown Brothers Harriman & Co. grew its stake in Genmab A/S by 143.4% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after acquiring an additional 780 shares during the last quarter. Finally, Osaic Holdings Inc. grew its stake in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after acquiring an additional 440 shares during the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Truist Financial began coverage on shares of Genmab A/S in a research report on Wednesday, May 27th. They set a “buy” rating and a $40.00 target price for the company. Weiss Ratings upgraded Genmab A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, July 28th. TD Cowen upgraded Genmab A/S from a “hold” rating to a “buy” rating and increased their target price for the company from $32.00 to $43.00 in a report on Wednesday, July 22nd. Guggenheim raised their price target on Genmab A/S from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Friday. Finally, HC Wainwright boosted their price target on Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $39.50.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB opened at $31.25 on Monday. The company has a market cap of $19.49 billion, a PE ratio of 24.61, a price-to-earnings-growth ratio of 1.95 and a beta of 0.83. Genmab A/S Sponsored ADR has a 12 month low of $21.00 and a 12 month high of $35.43. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44. The company has a 50-day simple moving average of $27.31 and a 200-day simple moving average of $27.98.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.17. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.12 billion. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. On average, equities analysts anticipate that Genmab A/S Sponsored ADR will post 1.11 earnings per share for the current year.

Key Headlines Impacting Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Royalty income lifted the outlook. Genmab’s drug-royalty revenue strengthened expectations for the business and was identified as a key reason the stock advanced. Genmab Stock Rises as Drug Royalties Lift Outlook
• Positive Sentiment: Q2 earnings exceeded expectations. Genmab reported EPS of $0.54, topping the $0.37 consensus estimate, while revenue of $1.16 billion surpassed expectations of $1.12 billion. The earnings beat reinforces the company’s profitability and operating momentum. Genmab Quarterly Earnings Results
• Positive Sentiment: Guggenheim raised its price target. The firm increased its target for GMAB from $40 to $42 and assigned a “Buy” rating, implying substantial upside from the stock’s recent trading level. Guggenheim Price Target Report
• Neutral Sentiment: Full-year revenue guidance is broadly in line with analyst expectations. Genmab guided to 2026 revenue of $4.3 billion to $4.5 billion, compared with consensus of approximately $4.4 billion. The range confirms continued growth but does not represent a major consensus reset. Genmab 2026 Q2 Results Presentation

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.